Comparison of the Efficacy of 75mg Aspirin Versus 150mg Aspirin in Pre- Prevention of Pre Eclampsia And its Complications in High Risk Pregnancy- A Study in a Tertiary Care Centre
Abstract
Introduction: Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin has been shown to reduce the risk of preeclampsia, pre-term birth, and fetal complications, particularly when started before 16 weeks of gestation in high-risk women Aims: To evaluate the efficacy of 75mg aspirin versus 150mgaspirin in prevention of pre eclampsia and its complications in high risk pregnant population. Materials and Methods: This observational study was conducted over 1.5 years at Nilratan Sircar Medical Col-lege, Kolkata, including 150 patients (75 in each group). Participants were followed at 24, 28, 32, 36 weeks, and weekly thereafter until delivery. The efficacy of two aspirin doses was evaluated in preventing preeclampsia and its complications. Result: In our study of 150 high-risk pregnant women, most were aged 21–25 years (39.3%) with primary edu-cation (42%). Baseline risk factors, including BMI ≤25, previous preeclampsia, and multifetal pregnancies, were similarly distributed between the two aspirin groups. Pregnancy complications occurred in 34% of participants, with gestational hypertension (21.3%) and preeclampsia (33–36%) being most common, while 68% showed a positive response to aspirin prophylaxis. Conclusion: We concluded that younger women with lower educational attainment made up a sizable share of the cohort in our study comparing 75 mg and 150 mg aspirin for the prevention of preeclampsia in high-risk pregnancies.Keywords:
Preeclampsia, High-risk pregnancy, Aspirin prophylaxis, Maternal outcomes, Dose comparisonReferences
1. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Obstet Gynecol. 2013;122(5):1122–31.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33(3): 130-7.
3. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010; 116(2 Pt 1):402–14.
4. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and meta-analysis. Am J Obstet Gynecol. 2018; 218(3): 287-93.el.
5. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2011.
6. National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133]; 2019.
7. ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132(1):e44–52.
8. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791–8.
9. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613–22.
10. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141–6.
11. Zhang Y, et al. Pregnancy with multiple high-risk factors: a systematic review. BMC Pregnancy Childbirth. 2025; 25(1):118.
12. McElrath TF, et al. Utility of the US Preventive Services Task Force for preeclampsia risk assessment and aspirin prophylaxis. JAMA Netw Open. 2025; 8(8):m e2530317.
13. Wang W, et al. Evaluation of low-dose aspirin on pregnancy outcomes. BMC Pregnancy Childbirth. 2025; 25(1):118.
Published
Abstract Display: 0 
PDF Downloads: 0 
